Baxter International Inc.

BAX

NYSE

31.23

USD

+0.95(+3.14%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Baxter International Inc. fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

-60.06

Price/Book

2.26

Debt/Equity

145.59%

Return on Equity

-7.58%

Dividend Yield

2.56%

EBITDA

1.12B

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	11,673,000,000	12,146,000,000	10,057,000,000	10,360,000,000	10,636,000,000
Gross Profit	4,587,000,000	4,720,000,000	3,549,000,000	4,150,000,000	3,984,000,000
Operating Income	1,616,000,000	1,350,000,000	-2,845,000,000	707,000,000	14,000,000
Net Income	1,102,000,000	1,284,000,000	-2,433,000,000	2,656,000,000	-649,000,000
Total Assets	20,019,000,000	33,521,000,000	28,287,000,000	28,276,000,000	25,782,000,000
Total Current Liabilities	3,333,000,000	4,236,000,000	4,745,000,000	6,503,000,000	6,511,000,000
Total Equity	8,726,000,000	9,121,000,000	5,895,000,000	8,468,000,000	7,024,000,000
Free Cash Flow	1,159,000,000	1,531,000,000	576,000,000	1,290,000,000	559,000,000
Cash from Operations	1,868,000,000	2,222,000,000	1,211,000,000	1,726,000,000	1,019,000,000
Cash from Investing	-1,179,000,000	-11,200,000,000	-931,000,000	3,213,000,000	-626,000,000
Cash from Financing	-345,000,000	8,245,000,000	-1,438,000,000	-3,489,000,000	-1,081,000,000
Net Change in Cash	401,000,000	-780,000,000	-1,234,000,000	1,476,000,000	-784,000,000

Baxter International Inc.

BAX

31.23

Baxter International Inc. fundamentals

Key ratios

Statements Highlights

Analyst Recomendations